1
|
Kojima S, Saito A, Sasaki F, Hayashi M, Mieno Y, Sakakibara H, Hashimoto S. Associations of self-efficacy and outcome expectancy with adherence to continuous positive airway pressure therapy in Japanese patients with obstructive sleep apnea. Fujita Med J 2023; 9:142-146. [PMID: 37234396 PMCID: PMC10206894 DOI: 10.20407/fmj.2022-015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 07/17/2022] [Indexed: 05/28/2023]
Abstract
Objective To examine the associations of self-efficacy and outcome expectancy with adherence to continuous positive airway pressure (CPAP) therapy among Japanese men with obstructive sleep apnea (OSA) using objective adherence data for CPAP therapy. Methods We conducted a retrospective study of 497 Japanese men with OSA who were receiving CPAP therapy. Good adherence was defined as CPAP use of ≥4 hours per night for ≥70% of nights. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations of good adherence to CPAP therapy with self-efficacy and outcome expectancy (measured with the CPAP Self-Efficacy Questionnaire for Sleep Apnea in Japanese). The models were adjusted for age, duration of CPAP therapy, body mass index, apnea-hypopnea index, Epworth Sleepiness Scale score, and comorbidities (diabetes mellitus and hypertension). Results In total, 53.5% of participants had good adherence to CPAP therapy. The mean CPAP use was 5.18±1.53 hours/night. After adjusting for related factors, we found significant associations of good adherence to CPAP therapy with self-efficacy scores (OR, 1.10; 95% CI, 1.05-1.13; p<0.001) and outcome expectancy scores (OR, 1.10; 95% CI, 1.02-1.15; p=0.007). Conclusions Our results indicate that self-efficacy and outcome expectancy are associated with good adherence to CPAP therapy among Japanese men with OSA.
Collapse
Affiliation(s)
- Shigeko Kojima
- Department of Rehabilitation, Faculty of Health Sciences, Nihon Fukushi University, Handa, Aichi, Japan
| | - Ayako Saito
- Department of Hygiene, Fujita Heath University, School of Medicine, Toyoake, Aichi, Japan
| | - Fumihiko Sasaki
- SDB Research Laboratory, Takaoka Clinic, Nagoya, Aichi, Japan
| | - Masamichi Hayashi
- Division of Respiratory Medicine, Fujita Health University Okazaki Medical Center, Okazaki, Aichi, Japan
| | - Yuki Mieno
- Department of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | | | - Shuji Hashimoto
- Department of Hygiene, Fujita Heath University, School of Medicine, Toyoake, Aichi, Japan
| |
Collapse
|
2
|
Kojima S, Saito A, Sasaki F, Hayashi M, Mieno Y, Sakakibara H, Hashimoto S. Associations of diabetes mellitus and hypertension with adherence to continuous positive airway pressure therapy in male patients with obstructive sleep apnea. Fujita Med J 2022; 8:37-41. [PMID: 35520293 PMCID: PMC9069265 DOI: 10.20407/fmj.2020-028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Accepted: 12/28/2020] [Indexed: 11/17/2022]
Abstract
Methods We conducted a retrospective study among 497 male patients with OSA on CPAP therapy. Participants with pretreatment Apnea-Hypopnea Index (AHI) data based on overnight polysomnographic recordings completed a questionnaire. Adherence data for CPAP therapy were collected using a smart card system. We classified CPAP use of ≥4 hours per night and ≥70% of nights as good adherence; other CPAP use was categorized as poor adherence. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for poor adherence to CPAP therapy in the hypertension and diabetes mellitus groups, compared with the no comorbidity group, adjusting for body mass index, duration of CPAP therapy, AHI, and Epworth Sleepiness Scale score. Results In the no comorbidity, hypertension, and diabetes mellitus groups, 43.4%, 44.7%, and 56.0%, respectively, had poor adherence to CPAP therapy. Being in the diabetes mellitus group was significantly associated with poor adherence to CPAP therapy (OR=1.86, 95% CI: 1.18-2.92, p=0.007); there was no association for the hypertension group. Conclusion Our results indicate that comorbidity of diabetes mellitus is associated with poor adherence to CPAP therapy in male patients with OSA.
Collapse
Affiliation(s)
- Shigeko Kojima
- Department of Rehabilitation, Faculty of Health Sciences, Nihon Fukushi University, Handa, Aichi, Japan
| | - Ayako Saito
- Department of Hygiene, School of Medicine, Fujita Heath University, Toyoake, Aichi, Japan
| | - Fumihiko Sasaki
- SDB Research Laboratory, Takaoka Clinic, Nagoya, Aichi, Japan
| | - Masamichi Hayashi
- Division of Respiratory Medicine, Fujita Health University Okazaki Medical Center, Okazaki, Aichi, Japan
| | - Yuki Mieno
- Department of Respiratory Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | | | - Shuji Hashimoto
- Department of Hygiene, School of Medicine, Fujita Heath University, Toyoake, Aichi, Japan
| |
Collapse
|
3
|
Mieno Y, Hayashi M, Hirochi M, Ikeda A, Kako H, Ina T, Maeda Y, Maeda S, Inoue T, Souma T, Watanabe T, Horiguchi T, Gotoh Y, Niwa Y, Yamatsuta K, Morikawa S, Sakakibara Y, Okamura T, Uozu S, Goto Y, Isogai S, Fujita S, Fukumoto J, Hosoda N, Imaizumi K. Availability of Home sleep apnea test equipment LS-140 on a comparison with Polysomnography. Fujita Med J 2022; 8:17-24. [PMID: 35233343 PMCID: PMC8874914 DOI: 10.20407/fmj.2020-014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 10/30/2020] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The prevalence of obstructive sleep apnea (OSA) in Japan is 9% among males and 3% among females. Up to 2.5 million patients are estimated to suffer from the disease, but limited number of facilities are capable of carrying out polysomnography (PSG), leaving more than 80% of these individuals are undiagnosed. In recent years, the development of new portable sleep monitoring (PMs) devices has been remarkable. We evaluate the correlation between the results of the LS-140 PMs device (Fukuda Denshi Tech Co. Ltd.), released in 2017, and those of PSG. METHODS We obtained contemporaneous data from the same patients by equipping 58 patients with PMs (LS-140) devices while they underwent PSG. Our primary outcome was Case 2 of the intraclass correlation coefficient (ICC), i.e., the ICC (2.1). And we used a Bland-Altman analysis to compare the apnea-hypopnea index (AHI) given by PSG and the respiratory event index (REI) given by LS-140 and examined the sensitivity and specificity of the REI relative to the AHI in the diagnosis of OSA. We also carried out the same comparison but in terms of the presence or absence of periodic limb movements (PLMs). RESULTS The ICC (2.1) between The REI and the AHI was 0.944, a rather high value (p<0.0001). The mean difference between AHI and REI values was -3.6 (p<0.0001), indicating a negative fixed bias. Sensitivity may decrease in groups with PLMs. CONCLUSION The REI and the AHI are highly correlated, giving LS-140 sufficient diagnostic sensitivity and specificity to screen for OSA.
Collapse
Affiliation(s)
- Yuki Mieno
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Masamichi Hayashi
- Fujita Health University Okazaki Medical Center, Okazaki, Aichi, Japan
| | - Mariko Hirochi
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Aki Ikeda
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Hisashi Kako
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Takuma Ina
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Yuri Maeda
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Shingo Maeda
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Takahiro Inoue
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Tomohide Souma
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Toshikazu Watanabe
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Tomoya Horiguchi
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Yusuke Gotoh
- Fujita Health University Okazaki Medical Center, Okazaki, Aichi, Japan
| | - Yoshikazu Niwa
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Kumiko Yamatsuta
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Sayako Morikawa
- Fujita Health University Okazaki Medical Center, Okazaki, Aichi, Japan
| | - Yosuke Sakakibara
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Takuya Okamura
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Sakurako Uozu
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Yasuhiro Goto
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Sumito Isogai
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| | - Shiho Fujita
- Fujita Health University Clinical Laboratory Center, Toyoake, Aichi, Japan
| | - Junichi Fukumoto
- Fujita Health University Clinical Laboratory Center, Toyoake, Aichi, Japan
| | - Nami Hosoda
- Fujita Health University Clinical Laboratory Center, Toyoake, Aichi, Japan
| | - Kazuyoshi Imaizumi
- Department of Respiratory Medicine Ⅰ, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
| |
Collapse
|
4
|
Okazawa M, Imaizumi K, Mieno Y, Takahashi H, Paré PD. Ratio of Maximal Inspiratory to Expiratory Flow Aids in the Separation of COPD from Asthma. COPD 2020; 17:230-239. [PMID: 32237910 DOI: 10.1080/15412555.2020.1742679] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Patients who have chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA) share symptoms such as, dyspnoea, cough and wheeze. Differentiating these diseases in the ambulatory setting can be challenging especially in older adult smokers who are being treated with a variety of medications. The objective of this study was to test the value of adding a maximal inspiratory manoeuvre to basic spirometry to differentiate COPD and BA. One hundred forty-three COPD patients and 142 BA patients had measurements of maximal inspiratory and expiratory flow during routine spirometry. Parameters from these tests were used to assess diagnostic accuracy using receiver-operating characteristic (ROC) analyses followed by logistic regression. The association of two independent parameters were analyzed using linear regression analyses. Results show that forced expiratory volume in one second/forced vital capacity (FEV1/FVC%) <62.4 was the best independent predictor to diagnose COPD. The combination of FEV1/FVC% <62.4 and the ratio of peak inspiratory flow/maximal expiratory flow at 50% FVC (PIF/MEF50) >3.06 significantly predicted COPD. Post-test probability for prediction of COPD was 82.0% when patients had both parameters. When asthmatic patients with a smoking history were compared with COPD patients, FEV1/FVC% <63.4 and PIF/MEF50 >3.29 were both independent predictors of COPD. The post-test probability for COPD was 94.4% when patients had both parameters. The association between FEV1/FVC% and PIF/MEF50 was significantly different between COPD and BA. In conclusion, the addition of the maximal inspiratory effort to routine pulmonary function measurements provides a simple test to help differentiate COPD and BA.
Collapse
Affiliation(s)
- Mitsushi Okazawa
- Department of Internal Medicine, Division of Respiratory Medicine and Clinical Allergy, Fujita Health University, Toyoake, Japan.,Daiyukai General Hospital, Daiyukai Health System, Ichinomiya, Japan
| | - Kazuyoshi Imaizumi
- Department of Internal Medicine, Division of Respiratory Medicine and Clinical Allergy, Fujita Health University, Toyoake, Japan
| | - Yuki Mieno
- Department of Internal Medicine, Division of Respiratory Medicine and Clinical Allergy, Fujita Health University, Toyoake, Japan
| | - Hiroshi Takahashi
- Division of Medical Statistics, Fujita Health University, Toyoake, Japan
| | - Peter D Paré
- University of British Columbia, Center for Heat Lung Innovation, St Paul's Hospital, Vancouver, Canada
| |
Collapse
|
5
|
Abstract
Objective Sleep apnea syndrome is more prevalent among men than women and is frequently accompanied by metabolic syndrome (MetS). However, gender differences in the effect of sleep-disordered breathing (SDB) leading to the risk of MetS remain unclear. The aim of our study was to investigate the clinical characteristics of SDB in women and the differential influence of SDB on MetS between genders. Methods In a single-center retrospective study, we compared the data of 1,809 consecutive SDB patients by gender to clarify the characteristics of sleep disorders in women. We also compared the prevalence of MetS and its related abnormalities by gender. A logistic regression analysis was used to determine the contributory factors for MetS. Results The mean age and proportion of patients over 50 years of age were higher in women than in men. SDB was milder in women than in men according to polysomnography findings. Elevated Hemoglobin A1c levels and hyperlipidemia were less frequent in women than in men. The MetS prevalence was similar in women and men (30.0% vs. 35.2%). A logistic regression analysis showed that the apnea-hypopnea index (AHI) was an independent risk factor for MetS in both genders, but that female gender was independently associated with a decreased prevalence of MetS and its related abnormalities. Conclusion Female SDB patients tend to be older with milder apnea and sleepiness than male SDB patients. A higher AHI is a significant risk factor for MetS in both genders, although female gender is an independent inhibitory factor for developing MetS in SDB patients.
Collapse
Affiliation(s)
- Yuki Mieno
- Department of Respiratory Medicine, Fujita Health University, Japan
| | | | | | | | - Shiho Fujita
- Department of Laboratory Medicine, Fujita Health University, Japan
| | - Sumito Isogai
- Department of Respiratory Medicine, Fujita Health University, Japan
| | - Yasuhiro Goto
- Department of Respiratory Medicine, Fujita Health University, Japan
| | - Sakurako Uozu
- Department of Respiratory Medicine, Fujita Health University, Japan
| | | | | |
Collapse
|
6
|
Isogai S, Niwa Y, Yatsuya H, Hayashi M, Yamamoto N, Okamura T, Minezawa T, Goto Y, Yamaguchi T, Takeyama T, Sakakibara Y, Morikawa S, Horiguchi T, Gotoh Y, Mieno Y, Uozu S, Nakanishi T, Okazawa M, Sakakibara H, Imaizumi K. Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma. Allergol Int 2017; 66:360-362. [PMID: 27816384 DOI: 10.1016/j.alit.2016.10.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Revised: 09/16/2016] [Accepted: 09/26/2016] [Indexed: 11/15/2022] Open
Affiliation(s)
- Sumito Isogai
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan.
| | - Yoshikazu Niwa
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Hiroshi Yatsuya
- Department of Public Health, Fujita Health University, Aichi, Japan
| | - Masamichi Hayashi
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Naoki Yamamoto
- Laboratory of Molecular Biology & Histochemistry, Fujita Health University, Aichi, Japan
| | - Takuya Okamura
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Tomoyuki Minezawa
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Yasuhiro Goto
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Teppei Yamaguchi
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Tomoko Takeyama
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Yosuke Sakakibara
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Sayako Morikawa
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Tomoya Horiguchi
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Yusuke Gotoh
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Yuki Mieno
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Sakurako Uozu
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Toru Nakanishi
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| | - Mitsushi Okazawa
- Department of Respiratory Medicine, Daiyukai General Hospital, Aichi, Japan
| | | | - Kazuyoshi Imaizumi
- Department of Respiratory Medicine, Fujita Health University, Aichi, Japan
| |
Collapse
|
7
|
Morikawa S, Okamura T, Minezawa T, Goto Y, Hayashi M, Yamaguchi T, Isogai S, Mieno Y, Yamamoto N, Uozu S, Nakanishi T, Okazawa M, Imaizumi K. A simple method of bronchial occlusion with silicone spigots (Endobronchial Watanabe Spigot; EWS®) using a curette. Ther Adv Respir Dis 2016; 10:518-524. [PMID: 27595645 PMCID: PMC5933595 DOI: 10.1177/1753465816664862] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background: Bronchial occlusion with an Endobronchial Watanabe Spigot (EWS) has been
shown to be useful in managing prolonged bronchopleural fistulas and
intractable hemoptysis. EWS bronchial occlusion using a curette is less
technically demanding. This retrospective study evaluated the clinical
utility and simplicity of this method. Methods: A total of 18 consecutive patients (15 men, 3 women, aged 47–85 years) who
underwent bronchial occlusion using an EWS from April 2012 to August 2014
were evaluated. The method involves sticking the tip of a curette into an
EWS to the first joint, allowing it to be turned in any direction or at any
angle. The time required to occlude the target bronchus was measured on
routinely recorded digital videos. Other parameters evaluated included
success rates, complications, and clinical outcomes. Results: Of the 18 patients, 11 underwent bronchial occlusion for intractable
pneumothorax, 5 for postoperative bronchopleural fistula, two for
intractable empyema, and one for hemoptysis. Each patient required 1–7 EWSs
(median 4). Target bronchi included the right upper (n =
8), left upper (n = 5), right lower (n =
2), left lower (n = 2), and right middle
(n = 1) bronchi. The success rate of EWS insertion into
the target bronchus was 100%. Time per EWS occlusion ranged from 65–528 sec
(median 158.5 sec). Of the 62 insertions, 36 (58.1%) were completed within 3
min, and 58 (93.5%) within 5 min. Successful outcomes were observed in 15
(83.3%) of the 18 patients. Conclusions: EWS bronchial occlusion using a curette is a simple method for managing
intractable bronchopleural fistulas in daily clinical settings.
Collapse
Affiliation(s)
- Sayako Morikawa
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Takuya Okamura
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Tomoyuki Minezawa
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Yasuhiro Goto
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Masamichi Hayashi
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Teppei Yamaguchi
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Sumito Isogai
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Yuki Mieno
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Naoki Yamamoto
- Laboratory of Molecular Biology and Histochemistry, Fujita Health University, Toyoake, Aichi, Japan
| | - Sakurako Uozu
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Toru Nakanishi
- Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan
| | - Mitsushi Okazawa
- Department of Respiratory Medicine and Clinical Allergy, Daiyukai General Hospital, Ichinomiya, Aichi, Japan
| | - Kazuyoshi Imaizumi
- Department of Respiratory Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan
| |
Collapse
|
8
|
Mieno Y, Kohno Y, Saita S, Ohno H. Frontispiece: Zwitterion/Brønsted Acid Mixtures Showing Controlled Lower Critical Solution Temperature-Type Phase Changes with Water. Chemistry 2016. [DOI: 10.1002/chem.201683561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Yuki Mieno
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| | - Yuki Kohno
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| | - Shohei Saita
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| | - Hiroyuki Ohno
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| |
Collapse
|
9
|
Mieno Y, Kohno Y, Saita S, Ohno H. Zwitterion/Brønsted Acid Mixtures Showing Controlled Lower Critical Solution Temperature-Type Phase Changes with Water. Chemistry 2016; 22:12262-5. [DOI: 10.1002/chem.201600973] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 05/16/2016] [Indexed: 11/07/2022]
Affiliation(s)
- Yuki Mieno
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| | - Yuki Kohno
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| | - Shohei Saita
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| | - Hiroyuki Ohno
- Department of Biotechnology; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
- Functional Ionic Liquid Laboratories, Graduate School of Engineering; Tokyo University of Agriculture and Technology, 2-24-16, Naka-cho, Koganei; Tokyo 184-8588 Japan
| |
Collapse
|
10
|
Minezawa T, Okamura T, Yatsuya H, Yamamoto N, Morikawa S, Yamaguchi T, Morishita M, Niwa Y, Takeyama T, Mieno Y, Hoshino T, Uozu S, Goto Y, Hayashi M, Isogai S, Matsuo M, Nakanishi T, Hashimoto N, Okazawa M, Imaizumi K. Bronchus sign on thin-section computed tomography is a powerful predictive factor for successful transbronchial biopsy using endobronchial ultrasound with a guide sheath for small peripheral lung lesions: a retrospective observational study. BMC Med Imaging 2015; 15:21. [PMID: 26092497 PMCID: PMC4475307 DOI: 10.1186/s12880-015-0060-5] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 05/19/2015] [Indexed: 11/10/2022] Open
Abstract
Background Recent advances in bronchoscopy, such as transbronchial biopsy (TBB) using endobronchial ultrasonography with a guide sheath (EBUS-GS), have improved the diagnostic yield of small-sized peripheral lung lesions. In some cases, however, it is difficult to obtain adequate biopsy samples for pathological diagnosis. Adequate prediction of the diagnostic accuracy of TBB with EBUS-GS is important before deciding whether bronchoscopy should be performed. Methods We retrospectively reviewed 149 consecutive patients who underwent TBB with EBUS-GS for small-sized peripheral lung lesions (≤30 mm in diameter) from April 2012 to March 2013. We conducted an exploratory analysis to identify clinical factors that can predict an accurate diagnosis by TBB with EBUS-GS. All patients underwent thin-section chest computed tomography (CT) scans (0.5-mm slices), and the CT bronchus sign was evaluated before bronchoscopy in a group discussion. The final diagnoses were pathologically or clinically confirmed in all studied patients (malignant lesions, 110 patients; benign lesions, 39 patients). Results The total diagnostic yield in this study was 72.5 % (95 % confidence interval: 64.8–79.0 %). Lesion size, lesion visibility on chest X-ray, and classification of the CT bronchus sign were factors significantly associated with the definitive biopsy result in the univariate analysis. In the multivariate analysis, only the CT bronchus sign remained as a significant predictive factor for successful bronchoscopic diagnosis. The CT bronchus sign was also significantly associated with the EBUS findings of the lesions. Conclusion Our results suggest that the CT bronchus sign is a powerful predictive factor for successful TBB with EBUS-GS.
Collapse
Affiliation(s)
- Tomoyuki Minezawa
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Takuya Okamura
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Hiroshi Yatsuya
- Department of Public Health, Fujita Health University, Toyoake, Aichi, Japan.
| | - Naoki Yamamoto
- Laboratory of Molecular Biology & Histochemistry, Fujita Health University, Toyoake, Aichi, Japan.
| | - Sayako Morikawa
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Teppei Yamaguchi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Mariko Morishita
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| | - Yoshikazu Niwa
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Tomoko Takeyama
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Yuki Mieno
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Tami Hoshino
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Sakurako Uozu
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Yasuhiro Goto
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Masamichi Hayashi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Sumito Isogai
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Masaki Matsuo
- Department of Respiratory Medicine, Chubu Rosai Hospital, Nagoya, Japan.
| | - Toru Nakanishi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| | - Naozumi Hashimoto
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| | - Mitsushi Okazawa
- Department of Respiratory Medicine, Daiyu-kai Hospital, Ichinomiya, Aichi, Japan.
| | - Kazuyoshi Imaizumi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| |
Collapse
|
11
|
Yamaguchi T, Isogai S, Okamura T, Uozu S, Mieno Y, Hoshino T, Goto Y, Hayashi M, Nakanishi T, Imaizumi K. Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. Case Rep Oncol 2015; 8:78-82. [PMID: 25848356 PMCID: PMC4361913 DOI: 10.1159/000375485] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
A 72-year-old man undergoing continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure and who had undergone right upper lobectomy for lung adenocarcinoma (pT2aN0M0) 2 years ago was admitted for recurrence of lung cancer presenting as multiple brain metastases. An epidermal growth factor receptor mutation analysis of his lung cancer revealed a deletion of 15 nucleotides (E746-A750) in exon 19. After whole-brain radiotherapy, we started daily administration of 250 mg gefitinib under the continuation of CAPD and performed a pharmacokinetic analysis. We speculated that the plasma concentration of gefitinib reached the steady state at least by day 16 after the start of gefitinib (626.6 ng/ml at trough level). On day 46, the plasma concentration was 538.4 ng/ml at trough level and the concentration in the peritoneal dialysis fluid was 34.6 ng/ml, suggesting that CAPD appeared to have little effect on the pharmacokinetics of gefitinib. During gefitinib therapy, there were no significant adverse events except for grade 2 diarrhea. Gefitinib could be safely administered to a patient undergoing CAPD.
Collapse
Affiliation(s)
- Teppei Yamaguchi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Sumito Isogai
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Takuya Okamura
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Sakurako Uozu
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Yuki Mieno
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Tami Hoshino
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Yasuhiro Goto
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Masamichi Hayashi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Toru Nakanishi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| | - Kazuyoshi Imaizumi
- Division of Respiratory Medicine and Clinical Allergy, Department of Internal Medicine, Fujita Health University, Toyoake, Japan
| |
Collapse
|
12
|
Yamaguchi T, Nakanishi T, Hayashi M, Uozu S, Okamura T, Morishita M, Takeyama T, Minezawa T, Morikawa S, Niwa Y, Mieno Y, Kato A, Hoshino T, Isogai S, Okazawa M, Imaizumi K. [Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer -- a retrospective analysis]. Gan To Kagaku Ryoho 2015; 42:183-187. [PMID: 25743136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advanced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regimen in Japanese patients in a daily clinical setting. METHODS We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. RESULTS Recorded Grade 3 or 4 hematological toxicities included neutropenia in 7 cases (17.5%), leukopenia in 5 cases (12.5%), anemia in 1 case (2.5%), thrombocytopenia in 1 case (2.5%), and febrile neutropenia in 1 case (2.5%). Grade 3 or 4 nonhematological toxicities included anorexia in 3 cases (7.5%), infection in 1 case (2.5%), rash in 1 case (2.5%), and increased transaminase expression in 1 case (2.5%). Therefore, the adverse events were mostly mild. There were no treatment related deaths. The overall response rate was 37.5%, median progression free survival was 5.6 months, and median overall survival (OS) was 18.8 months. In an epidermal growth factor receptor (EGFR) mutation status subgroup analysis, the median OS of patients with wild-type EGFR or unknown status (n=28)was 16.8 months. CONCLUSION Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC.
Collapse
Affiliation(s)
- Teppei Yamaguchi
- Division of Respiratory Medicine and Clinical Allergy, Dept. of Internal Medicine, Fujita Health University
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Saito A, Kojima S, Sasaki F, Hayashi M, Mieno Y, Sakakibara H, Hashimoto S. Development and evaluation of a self-efficacy instrument for Japanese sleep apnea patients receiving continuous positive airway pressure treatment. Nat Sci Sleep 2015; 7:25-31. [PMID: 25678832 PMCID: PMC4319555 DOI: 10.2147/nss.s74268] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The purpose of this study was to develop and evaluate a self-efficacy instrument for Japanese obstructive sleep apnea (OSA) patients treated with continuous positive airway pressure (CPAP). Analyzed subjects were 653 Japanese OSA patients (619 males and 34 females) treated with CPAP at a sleep laboratory in a respiratory clinic in a Japanese city. Based on Bandura's social cognitive theory, the CPAP Self-Efficacy Questionnaire for Sleep Apnea in Japanese (CSESA-J) was developed by a focus group of experts, using a group interview of OSA patients for the items of two previous self-efficacy scales for Western sleep apnea patients receiving CPAP treatment. CSESA-J has two subscales, one for self-efficacy and the other for outcome expectancy, and consists of a total of 15 items. Content validity was confirmed by the focus group. Confirmatory factor analysis showed that the factor loadings of self-efficacy and outcome expectancy were 0.47-0.76 and 0.41-0.92, respectively, for the corresponding items. CSESA-J had a significant but weak positive association with the General Self-Efficacy Scale, and a strong positive association with "Self-efficacy scale on health behavior in patients with chronic disease." Cronbach's alpha coefficient was 0.85 for the self-efficacy subscale and 0.89 for the outcome expectancy subscale. The intraclass correlation coefficient using data from the first and second measurements with CSESA-J for a subset of 130 subjects was 0.93 for the self-efficacy and outcome expectancy subscales. These results support CSESA-J as a reliable and valid instrument for measuring the self-efficacy of Japanese OSA patients treated with CPAP. Further studies are warranted to confirm validity for female OSA patients and generalizability.
Collapse
Affiliation(s)
- Ayako Saito
- Department of Hygiene, School of Medicine, Fujita Health University, Toyoake, Japan
| | - Shigeko Kojima
- Department of Rehabilitation, Faculty of Health Sciences, Nihon Fukushi University, Handa, Japan
| | | | - Masamichi Hayashi
- Department of Internal Medicine, Division of Respiratory Medicine and Clinical Allergy, Fujita Health University, Toyoake, Japan
| | - Yuki Mieno
- Department of Internal Medicine, Division of Respiratory Medicine and Clinical Allergy, Fujita Health University, Toyoake, Japan
| | | | - Shuji Hashimoto
- Department of Hygiene, School of Medicine, Fujita Health University, Toyoake, Japan
| |
Collapse
|
14
|
Saita S, Mieno Y, Kohno Y, Ohno H. Ammonium based zwitterions showing both LCST- and UCST-type phase transitions after mixing with water in a very narrow temperature range. Chem Commun (Camb) 2014; 50:15450-2. [DOI: 10.1039/c4cc06210h] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Ammonium-based zwitterions having adequate hydrophilicity showed both LCST- and UCST-type phase transitions after mixing with water.
Collapse
Affiliation(s)
- Shohei Saita
- Department of Biotechnology
- Tokyo University of Agriculture and Technology
- Tokyo 184-8588, Japan
- Functional Ionic liquid Laboratories
- Graduate School of Engineering
| | - Yuki Mieno
- Department of Biotechnology
- Tokyo University of Agriculture and Technology
- Tokyo 184-8588, Japan
- Functional Ionic liquid Laboratories
- Graduate School of Engineering
| | - Yuki Kohno
- Functional Ionic liquid Laboratories
- Graduate School of Engineering
- Tokyo University of Agriculture and Technology
- Tokyo 184-8588, Japan
| | - Hiroyuki Ohno
- Department of Biotechnology
- Tokyo University of Agriculture and Technology
- Tokyo 184-8588, Japan
- Functional Ionic liquid Laboratories
- Graduate School of Engineering
| |
Collapse
|
15
|
Shimizu H, Hayashi M, Saito Y, Mieno Y, Takeuchi Y, Sasaki F, Sakakibara H, Naito K, Okazawa M. Classification of chronic cough by systematic treatment cascade trial starting with beta agonist. Cough 2013; 9:4. [PMID: 23391257 PMCID: PMC3602065 DOI: 10.1186/1745-9974-9-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/30/2012] [Accepted: 02/03/2013] [Indexed: 11/10/2022]
Abstract
Background Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators. Objectives The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the β2 agonist and second to sub-categorize β2 agonist responsive cough (BRC) by the airway hyperresponsiveness. Methods One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made. Results One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study. Conclusions The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan. Trial registration University hospital medical information network
(UMIN 000007483)
Collapse
Affiliation(s)
- Hideyasu Shimizu
- Department of Internal Medicine, Division of Respiratory Medicine and Clinical Allergy, Fujita Health University, 1-98 Dengakugakubo Kutsukakecho, Toyoake, 470-1192, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, Kato A, Imizu H, Yoneda Y, Hoshino T, Uchiyama Y, Takeuchi Y, Okazawa M, Sakakibara H. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009; 64:1181-5. [PMID: 19377885 DOI: 10.1007/s00280-009-0981-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2008] [Accepted: 03/05/2009] [Indexed: 10/20/2022]
Abstract
PURPOSE To assess the efficacy and toxicity of an oral anticancer fluoropyrimidine derivative, S-1, for previously treated patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6 weeks. RESULTS Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% confidence interval (95%CI), 3.1-21.9%). Disease control rate was 39.6% (19/48) (95%CI, 25.7-53.4%). Median progression-free survival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxicities comprised neutropenia in one patient (2.1%) and anemia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only five patients (10.4%). Treatment-related death did not occur. CONCLUSION S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC.
Collapse
Affiliation(s)
- Yoshitaka Totani
- Division of Respirology and Allergology, Department of Internal Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake City, Aichi 470-1192, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Mieno Y. [Studies on plasma lipids. On the transesterification between cholesterol and lecithin in adult and infant plasma]. Sapporo Igaku Zasshi 1965; 28:15-24. [PMID: 5894475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|